Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer to end non-US...

    Bayer to end non-US sales of Essure, a contested sterilisation implant

    Written by Ruby Khatun Khatun Published On 2017-09-20T09:47:28+05:30  |  Updated On 20 Sept 2017 9:47 AM IST
    Bayer to end non-US sales of Essure, a contested sterilisation implant

    Paris: The pharmaceutical giant Bayer announced on Tuesday that it would end non-US sales of Essure, a sterilisation implant that in news reports has been linked to major side effects.


    "This decision is being taken for commercial reasons," the German group said.


    The withdrawal extended a decision taken in May to halt sales of the device in most countries where it was being marketed, it said.


    Essure, a non-hormonal coil implant used to sterilise women, has in some women caused chronic pain, perforation of the uterus and fallopian tubes and led to hysterectomies, news reports say.


    In its statement in French, Bayer insisted "this decision is not linked to any problem of safety or quality of the product... the safety and effectiveness of Essure is supported by more than 10 years of scientific research and real-life clinical settings."


    It added: "Bayer will continue to market the Essure medical device in the United States, where the FDA [Food and Drug Administration] recently assessed this device and concluded that the method had a favourable benefit-risk ratio."


    The European Union had already suspended sales of Essure in the 28-nation bloc for three months from August in response to the regulatory concern.


    Bayer said that, under today's decision, it would halt sales and distribution of the product "in all countries except the United States."


    In addition, it would not seek to renew its application for the "CE" marking -- the letters that are a commercial licence enabling the device to be sold across the EU.


    A tiny spring-shaped device, Essure is inserted under local anaesthetic into the fallopian tubes, blocking them in order to prevent fertilisation. It can be performed in the physician's office.


    Approved in the United States in 2002, its perceived advantage is that it is a less invasive alternative to tubal litigation, in which a small hole is cut into the abdomen and the surgeon blocks or cuts the fallopian tube.

    Bayercommercial reasoncontraceptive implantdeviceEssurefallopian tubeFDAfertilisationhaltsnon-US salespermanent birth controlsterilisation implantsterilise womentubal ligation
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok